The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
VJVirtual | INVICTUS: long-term results for ripritnanib as 4th-line therapy in advanced GIST
Robin Jones, MD, The Royal Marsden Hospital, London, UK, shares the long-term analysis of the Phase III INVICTUS (NCT03353753) trial investigating ripretinib in advanced gastrointestinal stromal tumor (GIST). The results showed a continued benefit of ripretinib in this patient population in regards to the primary endpoint, progression-free survival (PFS). The PFS rate at 6 months was 51% for patients receiving ripretinib versus 3.2% for patients receiving placebo and the 12 months PFS rate was 22.2% for ripretinib and not evaluable (NE) for placebo. At 18 months, the PFS rate was 11.8% in the ripretinib arm. The overall response rate (ORR) was 12% versus 0% for ripretinib versus placebo and overall-survival (OS) at 24 months was 42.8% compared to 19% for ripretinib and placebo, respectively. The long-term analysis of the INVICTUS trial confirmed the use of ripretinib in the fourth-line setting for the treatment of advanced GIST.
